Taxol complex preparation drug

A compound preparation, paclitaxel technology, applied in the field of medicine, can solve the problems of uncontrolled slow release time of the inner layer drug, injection toxicity, inner layer damage, etc. Effect

Inactive Publication Date: 2011-04-27
付金坤
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At the same time, it also solves the problems of toxicity and curative effect of injections
But, through the inventor's further practice, find that this structure still has the following problems: (1) in the industrial production process, add the outer layer capsule after producing the inner layer sustained-release soft capsule and face the technical problem that the inner layer is damaged; ( 2) If any mechanical or chemical damage is caused to the inner layer during the production process of adding the outer layer, after oral administration, the sustained release time of the drug in the inner layer will be out of control, thus affecting the curative effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Taxol complex preparation drug
  • Taxol complex preparation drug
  • Taxol complex preparation drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] like figure 1 As shown in the figure, the paclitaxel compound preparation drug, part of which is paclitaxel anticancer drug sustained-release capsule 1, and the other part is cyclosporine A rapid-release capsule 2; the two parts of the capsule are pressed together to become one and directly applied.

[0034] The preparation method is as follows:

[0035] 1) Preparation of paclitaxel anticancer drug sustained-release capsules: 1.5 grams of paclitaxel was dissolved in 10 grams of D-alpha-polyethylene glycol 1000 succinate (TPGS, D-alpha-tocopheryl polyethylene glycol 1000 succinate), followed by adding 5 grams of caprylic acid A mixture of polyethylene glycol glycerides and capric polyethylene glycol glycerides, 3 grams of sorbitan monooleate (Sorbitan monooleate), 0.2 grams of Ascorbyl palmitate (Ascorbyl palmitate) and 1 gram of absolute ethanol. This formula is mixed well for 100 unit doses. The obtained mixture and sustained-release capsules are pelleted through an ...

Embodiment 2

[0040] like image 3 As shown, a paclitaxel compound preparation drug, part of which is paclitaxel anticancer drug sustained-release capsule 1, and the other part is cyclosporine A rapid-release capsule 2; the two parts of the capsule are pressed together, and then coated with a layer of Capsule 3, becomes a composite capsule;

[0041] The preparation method is as follows:

[0042] 1) Preparation of paclitaxel anticancer drug capsules: 1 g of docetaxel was dissolved in 17 g of D-alpha-polyethylene glycol 1000 succinate (TPGS, D-alpha-tocopheryl polyethylene glycol 1000 succinate), followed by adding 3.5 g of caprylic acid A mixture of polyethylene glycol glycerides and capric polyethylene glycol glycerides, 2 grams of sorbitan monooleate (Sorbitan monooleate), 0.1 grams of Ascorbyl palmitate (Ascorbyl palmitate) and 0.5 grams of absolute ethanol. This formula is mixed well for 100 unit doses. The obtained mixture and capsules are pelleted through an automatic soft capsule m...

Embodiment 3

[0047] like Figure 5 As shown in the figure, a paclitaxel compound preparation drug, one part is the paclitaxel anticancer drug capsule 1, and the other part is the cyclosporine A capsule 2; the two parts of the capsule are pressed together to become one, and can be directly applied.

[0048] Preparation:

[0049] 1) Preparation of paclitaxel anticancer drug capsules: 1 g of docetaxel was dissolved in 17 g of D-alpha-polyethylene glycol 1000 succinate (TPGS, D-alpha-tocopheryl polyethylene glycol 1000 succinate), followed by adding 3.5 g of caprylic acid A mixture of polyethylene glycol glycerides and capric polyethylene glycol glycerides, 2 grams of sorbitan monooleate (Sorbitan monooleate), 0.1 grams of Ascorbyl palmitate (Ascorbyl palmitate) and 0.5 grams of absolute ethanol. This formula is mixed well for 100 unit doses. The obtained mixture and capsules are pelleted through an automatic soft capsule machine, rolled and shaped, dried at 20-30° C., selected for pills, wa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a taxol complex preparation drug. Based on the technical scheme, one part of the taxol complex preparation drug is a taxol anticancer drug capsule, the other part is a cyclosporine A capsule, and the two capsules are pressed together, or the two capsules are wrapped by a layer of capsule after being pressed to form a compound capsule. A preparation method of the taxol complex preparation drug has the following steps of taxol anticancer drug capsule preparation: uniformly mixing taxol active substances and a drug excipient according to the proportion of a taxol anticancer drug, and wrapping the mixture in a capsule; cyclosporine A capsule preparation: uniformly mixing cyclosporin A and a matched excipient according to the proportion of a cyclosporine A drug, and wrapping the mixture in a capsule; preparation of a complex preparation: pressing the capsules prepared in the two steps together, and directly applying; or wrapping the two capsules with a layer of capsule after being pressed to form the compound capsule. The invention has the advantages of mature production, convenience in orally taking, easier quality control and good anticancer therapeutic efficacy.

Description

Technical field: [0001] The invention relates to the field of medicine, in particular to an anticancer paclitaxel compound preparation medicine with a compound structure. Background technique: [0002] The inventors of the present application have been devoted to the research and development of paclitaxel-based anticancer drugs. In the early research and development work, the inventor of the present invention applied in 2008: the application number is 200810010439.7; in the patent with the name of the invention "Paclitaxel-based Double-layer Soft Capsule Oral Preparation Drugs", as the inventor, he developed a A double-layer soft capsule oral preparation drug. In this patent application, the preparation is a double-layer capsule, that is, the inner layer is the anticancer drug of paclitaxel, the outer layer is the drug cyclosporine A, and the preparation structure is the inner and outer layers. Solved: In the course of treatment, avoid using cyclosporine A first, then pacl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/13A61K9/48A61P35/00A61K31/337
Inventor 蔺新力
Owner 付金坤
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap